RNS Number : 2516T
Incanthera PLC
20 June 2024
 

 

Goal Group

 

                                                                                                                                                                         20 June 2024

 

                                                                                       Incanthera plc                                              

("Incanthera" the "Company")

Result of General Meeting

 

Incanthera plc (AQSE: INC), the specialist oncology company focused on innovative technologies in oncology and dermatology announces the results of a general meeting ("General Meeting") held at 11am today.

 

The General Meeting follows the company's announcement on 3 June 2024, of a conditional subscription for £2.6 million, which was subject to shareholder approval.

 

The Company is pleased to announce that all resolutions were duly passed.

 

For further information please contact:

 

Incanthera plc

www.incanthera.com

 

Tim McCarthy, Chairman

tim.mccarthy@incanthera.com

 

Simon Ward, Chief Executive Officer

simon.ward@incanthera.com

 

Suzanne Brocks, Head of Communications

suzanne.brocks@incanthera.com

 

 

 

+44 (0) 7831 675747

 

 

+44 (0) 7747 625506

 

 

+44 (0) 7776 234600



Aquis Exchange Corporate Adviser: 

Cairn Financial Advisers LLP

Jo Turner / Liam Murray / Ed Downes

+44 (0) 20 7213 0880

 


Broker: 

Stanford Capital Partners Ltd

Patrick Claridge / Bob Pountney

+44 (0) 20 3650 3650/51

 

Notes to Editors

 

About Incanthera plc

 

Incanthera is a specialist company focused on innovative technologies in dermatology and oncology. It seeks to identify and develop innovative solutions to current clinical, commercially relevant unmet needs, utilising new technology from leading specialists and academic institutions as well as its in-house development team.

 

The Company originated from the Institute of Cancer Therapeutics ("ICT") at the University of Bradford.  Incanthera's strategy is to develop each candidate in its portfolio from initial acquisition or discovery to securing its future through commercially valuable partnerships at the earliest opportunity in its development pathway.

                                                                                                               

For more information on the Company please visit: www.incanthera.com

 

@incantheraplc

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NEXURORRSBUNUAR
Incanthera (AQSE:INC)
Gráfica de Acción Histórica
De Dic 2024 a Dic 2024 Haga Click aquí para más Gráficas Incanthera.
Incanthera (AQSE:INC)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024 Haga Click aquí para más Gráficas Incanthera.